Affordable Access

deepdyve-link
Publisher Website

18F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma.

Authors
  • Crompton, Joseph1
  • Armstrong, Wesley R1
  • Eckardt, Mark A2
  • Seyedroudbari, Ameen1
  • Tap, William D3
  • Dry, Sarah M1
  • Abt, Evan R1
  • Calais, Jeremie1
  • Herrmann, Ken4
  • Czernin, Johannes1
  • Eilber, Fritz C1
  • Benz, Matthias R1
  • 1 University of California Los Angeles, United States. , (United States)
  • 2 Yale School of Medicine.
  • 3 Memorial Sloan Kettering Cancer Center (MSKCC).
  • 4 University of Duisburg-Essen.
Type
Published Article
Publication Date
Sep 30, 2021
Identifiers
DOI: 10.2967/jnumed.121.262502
PMID: 34593596
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Purpose: The purpose of this study was to evaluate 18F-FLT PET/CT as an early prognostic imaging biomarker of long-term overall survival (OS) and disease-specific survival (DSS) in soft tissue sarcoma (STS) patients treated with neoadjuvant therapy (NAT) and surgical resection. Methods: This is a 10-year follow up of a previous, single-center, single-arm, prospective clinical trial. Patients underwent 18F-FLT PET/CT prior to treatment (PET1) and after NAT (PET2). Post-treatment pathology specimens were assessed for tumor necrosis / fibrosis as well as Ki-67 and TK1 expression. Maximally selected cut-offs for PET and histopathologic factors were applied. Survival was calculated from the date of subject consent to the date of death or last follow-up. Results: The study population consisted of 26 patients who underwent PET1, 16/26 primary STS underwent PET2. Thirteen deaths occurred during a median follow up period of 104 months. In the overall cohort, OS was longer in patients with low versus high PET1 tumor SUVmax (dichotomized by SUVmax ≥ 8.5 vs. < 8.5; not yet reached vs. 49.7 months; P = 0.0064). DSS showed a trend toward significance (P = 0.096). In a sub-analysis of primary STS, DSS was significantly longer in patients with low versus high PET1 tumor SUVmax (dichotomized by SUVmax ≥ 8 vs < 8; P = 0.0034). There were no significant 18F-FLT PET response thresholds corresponding to DSS or OS following NAT at PET2. Conclusion: 18F-FLT PET may serve as prognostic baseline imaging biomarker for DSS in patients with primary STS. Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Report this publication

Statistics

Seen <100 times